
Opinion|Videos|September 1, 2023
Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS
Author(s)Eytan M. Stein, MD
Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5













































